Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia

Manabu Yamamoto, Tetsuya Kusumoto, Kazuya Endo, Hideo Baba, Yoshihisa Sakaguchi, Yoshihiko Maehara, Keizo Sugimachia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The combined effects of flavone acetic acid (FAA), hydralazine (HYD) and hyperthermia on B16 melanoma cells and solid tumor were examined in vitro and in vivo. In vitro, hyperthermia did not enhance the cytotoxicity of the combined use of FAA and HYD. In vivo, growth inhibition of B16 melanoma solid tumor by FAA (150 mg/kg) combined with HYD (5.0 mg/kg) could not be differentiated from that by FAA or HYD alone. Increased antitumor effect was recognized when FAA combined with HYD was used under conditions of hyperthermia. FAA combined with HYD significantly reduced tumor blood flow compared to FAA alone or HYD alone. We thus conclude that the significant reduction in tumor blood flow may play an important role in the enhanced antitumor effects of the combined treatment with FAA, HYD, and hyperthermia.

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalOncology (Switzerland)
Volume53
Issue number2
DOIs
Publication statusPublished - Jan 1 1996

Fingerprint

flavone acetic acid
Hydralazine
Fever
Experimental Melanomas
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia. / Yamamoto, Manabu; Kusumoto, Tetsuya; Endo, Kazuya; Baba, Hideo; Sakaguchi, Yoshihisa; Maehara, Yoshihiko; Sugimachia, Keizo.

In: Oncology (Switzerland), Vol. 53, No. 2, 01.01.1996, p. 147-152.

Research output: Contribution to journalArticle

Yamamoto, M, Kusumoto, T, Endo, K, Baba, H, Sakaguchi, Y, Maehara, Y & Sugimachia, K 1996, 'Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia', Oncology (Switzerland), vol. 53, no. 2, pp. 147-152. https://doi.org/10.1159/000227551
Yamamoto, Manabu ; Kusumoto, Tetsuya ; Endo, Kazuya ; Baba, Hideo ; Sakaguchi, Yoshihisa ; Maehara, Yoshihiko ; Sugimachia, Keizo. / Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia. In: Oncology (Switzerland). 1996 ; Vol. 53, No. 2. pp. 147-152.
@article{5411ee64b70643f3a4bc3628757d920e,
title = "Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia",
abstract = "The combined effects of flavone acetic acid (FAA), hydralazine (HYD) and hyperthermia on B16 melanoma cells and solid tumor were examined in vitro and in vivo. In vitro, hyperthermia did not enhance the cytotoxicity of the combined use of FAA and HYD. In vivo, growth inhibition of B16 melanoma solid tumor by FAA (150 mg/kg) combined with HYD (5.0 mg/kg) could not be differentiated from that by FAA or HYD alone. Increased antitumor effect was recognized when FAA combined with HYD was used under conditions of hyperthermia. FAA combined with HYD significantly reduced tumor blood flow compared to FAA alone or HYD alone. We thus conclude that the significant reduction in tumor blood flow may play an important role in the enhanced antitumor effects of the combined treatment with FAA, HYD, and hyperthermia.",
author = "Manabu Yamamoto and Tetsuya Kusumoto and Kazuya Endo and Hideo Baba and Yoshihisa Sakaguchi and Yoshihiko Maehara and Keizo Sugimachia",
year = "1996",
month = "1",
day = "1",
doi = "10.1159/000227551",
language = "English",
volume = "53",
pages = "147--152",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Vasoacting Agents Flavone Acetic Acid and Hydralazine Given in Combination Enhance Antitumor Effects under Condition of Hyperthermia

AU - Yamamoto, Manabu

AU - Kusumoto, Tetsuya

AU - Endo, Kazuya

AU - Baba, Hideo

AU - Sakaguchi, Yoshihisa

AU - Maehara, Yoshihiko

AU - Sugimachia, Keizo

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The combined effects of flavone acetic acid (FAA), hydralazine (HYD) and hyperthermia on B16 melanoma cells and solid tumor were examined in vitro and in vivo. In vitro, hyperthermia did not enhance the cytotoxicity of the combined use of FAA and HYD. In vivo, growth inhibition of B16 melanoma solid tumor by FAA (150 mg/kg) combined with HYD (5.0 mg/kg) could not be differentiated from that by FAA or HYD alone. Increased antitumor effect was recognized when FAA combined with HYD was used under conditions of hyperthermia. FAA combined with HYD significantly reduced tumor blood flow compared to FAA alone or HYD alone. We thus conclude that the significant reduction in tumor blood flow may play an important role in the enhanced antitumor effects of the combined treatment with FAA, HYD, and hyperthermia.

AB - The combined effects of flavone acetic acid (FAA), hydralazine (HYD) and hyperthermia on B16 melanoma cells and solid tumor were examined in vitro and in vivo. In vitro, hyperthermia did not enhance the cytotoxicity of the combined use of FAA and HYD. In vivo, growth inhibition of B16 melanoma solid tumor by FAA (150 mg/kg) combined with HYD (5.0 mg/kg) could not be differentiated from that by FAA or HYD alone. Increased antitumor effect was recognized when FAA combined with HYD was used under conditions of hyperthermia. FAA combined with HYD significantly reduced tumor blood flow compared to FAA alone or HYD alone. We thus conclude that the significant reduction in tumor blood flow may play an important role in the enhanced antitumor effects of the combined treatment with FAA, HYD, and hyperthermia.

UR - http://www.scopus.com/inward/record.url?scp=0029986582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029986582&partnerID=8YFLogxK

U2 - 10.1159/000227551

DO - 10.1159/000227551

M3 - Article

VL - 53

SP - 147

EP - 152

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -